Cortex Pharmaceuticals Inc. said it has received a patent for theuse of the protein spectrin as a marker for the degeneration ofbrain cells. The Irvine, Calif., company is attempting to developa spectrin-based immunoassay that would detectneurodegenerative conditions more cheaply than imagingscans, which cost $500 to $1,500 per procedure.

(c) 1997 American Health Consultants. All rights reserved.